An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CFTM 1 Source: ERJ Open Res, 6 (4) 00395-2020; 10.1183/23120541.00395-2020 Year: 2020
Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study Source: Eur Respir J, 59 (2) 2100746; 10.1183/13993003.00746-2021 Year: 2022
Safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor, following single- and multiple-ascending doses in healthy volunteers and mild asthmatics Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021
Safety, tolerability and pharmacokinetics (PK) of AZD8154 (a selective PI3K?d inhibitor) after single ascending inhaled doses in healthy volunteers Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019
Preclinical evaluation of the epithelial sodium channel inhibitor BI 1265162 for treatment of cystic fibrosis Source: ERJ Open Res, 6 (4) 00429-2020; 10.1183/23120541.00429-2020 Year: 2020
Safety, tolerability and pharmacokinetics of AZD9668, an oral neutrophil elastase inhibitor, in healthy subjects and patients with COPD Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Aminoguanidine inhibits bronchial NO production, but not diffusion or alveolar NO in patients with asthma, smokers and healthy volunteers Source: Eur Respir J 2004; 24: Suppl. 48, 577s Year: 2004
PUR1800 (RV1162), A novel narrow spectrum kinase inhibitor, but not Fluticasone, reduces TNFa-induced cytokine release by primary bronchial epithelial cells from healthy volunteers and COPD patients Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018
Tolerability and pharmacokinetics of inhaled bimosiamose in healthy human volunteers Source: Eur Respir J 2006; 28: Suppl. 50, 332s Year: 2006
Modulation of NK receptors by budesonide and/or formoterol in healthy volunteers and COPD patients Source: Annual Congress 2011 - COPD: clinical studies and animal cell models Year: 2011
Effects on adrenal function of a new combination of fluticasone propionate/formoterol fumarate administered to asthmatic patients and healthy subjects Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011
A randomised placebo controlled trial to evaluate the effects of butamirate and dextromethorphan on capsaicin induced cough in healthy volunteers Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013
Comparison of magnesium sulfate to normal saline as a vehicle for nebulized salbutamol in children with acute asthma; a clinical trial Source: Annual Congress 2008 - Treatment and outcome of childhood asthma: new perspectives Year: 2008
Changes in biomarkers with nintedanib plus sildenafil in subjects with IPF by presence of emphysema in the INSTAGE trial Source: Virtual Congress 2020 – Promising biomarkers for idiopathic interstitial pneumonia Year: 2020
Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009
Equivalent bone safety and better efficacy of fluticasone propionate compared to nedocromil sodium in asthmatic children. Results of a 2-year randomized study Source: Eur Respir J 2002; 20: Suppl. 38, 219s Year: 2002
A randomized clinical trial of magnesium sulfate as a vehicle for nebulized salbutamol in the treatment of moderate to severe asthma attacks Source: Eur Respir J 2004; 24: Suppl. 48, 343s Year: 2004
Efficacy and safety of montelukast sodium on adult bronchial asthma in a multicentre comparative double-blind clinical study with pranlukast hydrate Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002
Effects of the CFTR potentiator, ivacaftor, in two phase 3 trials in subjects with CF who have the G551D-CFTR mutation Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new therapies and detection of early lung disease Year: 2012
Efficacy and safety of montelukast sodium on adult bronchial asthma in a multicenter comparative double-blind clinical study with pranlukast hydrate Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001